Tofacitinib et risque de tumeur maligne : Résultats de l'étude sur l'innocuité du tofacitinib chez les patients atteints de polyarthrite rhumatoïde et recevant des soins de routine (STAR-RA)
Arthritis Rheumatol. 2022;74:1648–1659 doi: 10.1002/art.42250
Large, population-based, real-world cohort of study in patients with RA finds tofacitinib not to be associated with an increased risk of malignancies, in comparison to TNFi agents, although a numerically increased risk of malignancies was observed in older patients with risk factors for cardiovascular disease.
Tofacitinib et risque d'accident cardiovasculaire : résultats de l'étude "Safety of Tofacitinib in Routine care patients with Rheumatoid Arthritis" (STAR-RA) (Innocuité du tofacitinib dans les soins de routine aux patients atteints de polyarthrite rhumatoïde)
Ann Rheum Dis. 2022 Jan 13. Epub ahead of print doi: 10.1136/annrheumdis-2021-221915Real-world evidence finds no increased risk of CV outcomes with tofacitinib, in comparison with TNFi, in patients with RA. However, an elevated risk of CV outcomes cannot be ruled out in patients with CV risk factors or history of CVD.Recent post-marketing findings from the ‘ORAL Surveillance’ trial have raised concerns that tofacitinib, in comparison with TNFi, may increase the risk of CV disease in patients with RA who are at least 50 years of age and with at least one risk factor for CVD. To ...